This research does not address programs that seek to deprescribe GLP-1 medications, since peer reviewed studies of such programs are not yet available
This article will move beyond the basics of semaglutide injection sites
While metformin remains the first-line treatment for type 2 diabetes, healthcare providers may recommend GLP-1 agonists in various scenarios
Current evidence does not support routine clinical use of GLP-1 medications specifically for alcohol cravings, and patients with alcohol use disorder should be referred to evidence-based treatments including behavioral interventions, mutual support groups, and FDA-approved pharmacotherapies such as naltrexone, acamprosate, and disulfiram
10 Semaglutide is noteworthy for research due to its superior efficacy (15% weight loss within one year versus 510% with earlier agents 1116 ), unique pharmacokinetic profile resulting from its modified molecular structure, 17 and rapid adoption, particularly among populations without diabetes
doi: 10.3389/fimmu.2018.01291 15 GrahamDLMadkourHSNobleBLSchatschneiderCStanwoodGD